To investigate the clinical effect of superselective renal artery embolization in treatment of hematuria with renal cancer.

Retrospective analysis on 39 cases (22 males and 17 females) of hematuria with renal cancer treated in our hospital from January 2015 to January 2018 were selected. All patients were diagnosed as renal cell carcinoma hematuria by auxiliary examination and underwent superselective renal artery embolization. Blood and urine samples were collected on the 2^nd, 7^th, 14^th and 21^st postoperative day for routine blood and urine tests.

Thirty-nine patients were embolized with super liquid iodine oil + gelatin sponge particles. All of them were successfully embolized with a success rate of 100%. Among them, 21 patients had gross hematuria disappeared after 12 hours and 18 patients had gross hematuria eared after 24 hours after embolization. On the 2^nd, 7^th, 14^th and 21^st postoperative day, the levels of red blood cell count (RBC) , hemoglobin (Hb) and hematocrit (HCT) were higher than those before surgery, and the urine RBC was lower than that before surgery with statistically significant differences (P<0.01) . All the 39 patients had embolism syndrome after embolization. The clinical manifestations of nausea, vomiting, fever and low back pain were disappeared after symptomatic treatment for 2 to 5 days. 38 patients were followed up for 3 to 12 months. No complications such as ectopic embolization, acute renal failure, renal necrosis or renal abscess occurred.

Superselective renal artery embolization can terminate hematuria in patients with renal cell carcinoma, and has the advantages of minimally invasive, safety and reliability, and fewer complications.